Efficacy and Safety of Ivonescimab in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): A Systematic Review

Abstract

This systematic review critically evaluates the safety and efficacy of the novel drug Ivonescimab in the treatment of advanced and metastatic non-small cell lung cancer (NSCLC). Ivonescimab showed promising antitumor activity and improved clinical outcomes, particularly in patients with higher PD-L1 expression levels and those receiving second-line therapy. The findings suggest its potential to overcome resistance to PD-1/PD-L1 inhibitors while offering a manageable safety profile. Common adverse events were observed, highlighting the need for further research to refine dosing strategies and optimize patient selection. Future studies should focus on long-term outcomes and real-world applications to better establish the role of Ivonescimab in NSCLC management.